Administración de la Profilaxis con Palivizumab y Desenlaces Respiratorios en Pacientes Pediátricos de Alto Riesgo en el Hospital General de Cancún, Quintana Roo, México
Sciencevolution · 30.09.2026 · 5 (3) · 61-75
DOI: 10.61325/c20pdd36 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sciencevolution, online erschienen am 30.09.2026. Verfasst von Alexia Paola Leyva Ramírez und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) causes lower respiratory tract infections and hospitalization in children under five years of age, with a higher risk of severe disease among preterm infants and patients with cardiopulmonary comorbidities. Palivizumab reduces RSV-associated hospitalizations in high-risk pediatric populations; however, its effectiveness may depend on adherence to and timely administration of the prophylactic regimen. The objective was to evaluate the association between adherence to palivizumab prophylaxis and respiratory outcomes during the six months following the first dose, with respiratory hospitalization considered the primary outcome. A quantitative, observational, analytical, longitudinal, retrospective cohort study was conducted using census sampling. Fifty patients treated between 2023 and 2026 were included, six (12.0%) with complete and timely prophylaxis and 44 (88.0%) with incomplete or untimely prophylaxis. For the primary outcome, 49 patients were evaluable. Respiratory hospitalization occurred in 0/6 patients (0%) with complete and timely prophylaxis and in 13/43 (30.2%) with incomplete or untimely prophylaxis; the difference did not reach statistical significance (p = 0.175). A lower frequency of respiratory hospitalization was observed in the complete and timely prophylaxis group, although this finding should be interpreted with caution because of the small sample size.
Zitieren
APA
Ramírez, A. P. L., & López, E. H. (2026). Administración de la Profilaxis con Palivizumab y Desenlaces Respiratorios en Pacientes Pediátricos de Alto Riesgo en el Hospital General de Cancún, Quintana Roo, México. Sciencevolution, 5(3), 61-75. https://doi.org/10.61325/c20pdd36
Vancouver
Ramírez APL, López EH. Administración de la Profilaxis con Palivizumab y Desenlaces Respiratorios en Pacientes Pediátricos de Alto Riesgo en el Hospital General de Cancún, Quintana Roo, México. Sciencevolution. 2026;5(3):61-75. doi:10.61325/c20pdd36
BibTeX
@article{Ramrez2026,
author = {Ramírez, Alexia Paola Leyva and López, Eduardo Herrera},
title = {Administración de la Profilaxis con Palivizumab y Desenlaces Respiratorios en Pacientes Pediátricos de Alto Riesgo en el Hospital General de Cancún, Quintana Roo, México},
journal = {Sciencevolution},
year = {2026},
volume = {5},
number = {3},
pages = {61--75},
doi = {10.61325/c20pdd36}
}
EUVIMED